Michael R. Rickels

faculty photo
Professor of Medicine at the Hospital of the University of Pennsylvania
Medical Director, Pancreatic Islet Cell Transplant Program, Hospital of the University of Pennsylvania
Associate Director, Center for Human Phenomic Science (formerly the Clinical & Translational Research Center), University of Pennsylvania
Director, Translational Research Program, Institute for Diabetes, Obesity & Metabolism, Perelman School of Medicine, University of Pennsylvania
Director, Radioimmunoassay and Biomarkers Core, Diabetes Research Center, Perelman School of Medicine, University of Pennsylvania
Department: Medicine

Contact information
12-134 Smilow Center for Translational Research
3400 Civic Center Boulevard
Philadelphia, Pa 19104
Office: (215) 746-0025
Fax: (215) 898-5408
Education:
B.A. (Mathematics major & Biology minor, Summa Cum Laude)
Colgate University , 1995.
M.D. (Top of the class)
University of Pennsylvania School of Medicine, 1999.
M.S. (Translational Research)
University of Pennsylvania School of Medicine, 2007.
Permanent link
 

Description of Research Expertise

Dr. Rickels conducts patient-oriented diabetes research that aims at understanding the pathogenesis of various forms of diabetes and the in vivo mechanisms of new diabetes treatments, and is in particular focused on islet function and replacement in type 1 diabetes and pancreatogenic forms of diabetes. Dr. Rickels' studies involve methodologies for quantifying insulin and incretin secretion, insulin sensitivity, and glucose counterregulatory responses to hypoglycemia, and include oral glucose and mixed-meal tolerance tests, the frequently-sampled intravenous glucose tolerance test, the glucose-potentiated arginine test, and hyperinsulinemic euglycemic and hypoglycemic clamps. Present work in type 1 diabetes is focused on understanding the mechanisms of defective glucose counterregulation and novel approaches to the prevention or correction of hypoglycemia, including by beta-cell replacement (islet transplantation) therapy or artificial pancreas (closed-loop) technology. Present work in cystic fibrosis-related diabetes is directed at understanding the pathophysiologic defects involved in the etiology of early defects in insulin secretion and the impact of different strategies for enhancing incretin effects on beta-cell function.

Selected Publications

Vantyghem MC, de Koning EJP, Pattou F, Rickels MR: Advances in beta-cell replacement therapy for the treatment of type 1 diabetes. Lancet 394(10205): 1274-1285, October 2019.

Rickels MR: Hypoglycemia associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes. Annals of the New York Academy of Sciences 1454(1): 68-79, October 2019.

Rickels MR, Robertson RP: Pancreatic islet transplantation in humans: recent progress and future directions. Endocrine Reviews 40(2): 631-688, April 2019 Notes: Endocrine Society Thematic Issue on Diabetes.

Kelly A, De Leon DD, Sheikh S, Camburn D, Kubrak C, Peleckis AJ, Stefanovski D, Hadjiliadis D, Rickels MR, Rubenstein RC: Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy. American Journal of Respiratory and Critical Care Medicine 199(3): 342-351, February 2019.

Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, Maahs DM, Tamborlane WV, Bergenstal R, Smith E, Olson BA, Garg SK; T1D Exchange Clinic Network: State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018. Diabetes Technology & Therapeutics 21(2): 66-72, February 2019.

Korutla L, Rickels MR, Hu RW, Habertheuer A, Reddy S, Freas A, Harmon J, Korutla V, Ram C, Naji A, Vallabhajosyula P: Noninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation. American Journal of Transplantation 19(6): 1852-1858, June 2019.

Nyirjesy SC,* Sheikh S,* Hadjiliadis D, De Leon DD, Peleckis AJ, Eiel JN, Kubrak C, Stefanovski D, Rubenstein RC, Rickels MR, Kelly A : Beta-cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥155 mg/dl. Pediatric Diabetes 19(7): 1173-1182, November 2018 Notes: *Contributed equally as primary authors.

Odorico J, Markmann J, Melton D, Greenstein J, Hwa A, Nostro C, Rezania A, Oberholzer J, Pipeleers D, Yang L, Cowan C, Huangfu D, Egli D, Ben-David U, Vallier L, Grey ST, Tang Q, Roep B, Ricordi C, Naji A, Orlando G, Anderson DG, Poznansky M, Ludwig B, Tomei A, Greiner DL, Graham M, Carpenter M, Migliaccio G, D'Amour K, Hering B, Piemonti L, Berney T, Rickels M, Kay T, Adams A: Report of the Key Opinion Leaders Meeting on Stem Cell-Derived Beta Cells. Transplantation 102(8): 1223-1229, August 2018.

Rickels MR, DuBose SN, Toschi E, Beck RW, Verdejo AS, Wolpert H, Cummins MJ, Newswanger B, Riddell MC; T1D Exchange Mini-Dose Glucagon Exercise Study Group: Mini-dose glucagon as a novel approach to prevent exercise-induced hypoglycemia in type 1 diabetes. Diabetes Care 41(9): 1909-1916, September 2018.

Rickels MR, Peleckis AJ, Dalton-Bakes C, Naji JR, Ran NA, Nguyen H-L, O'Brien S, Chen S, Lee I, Schutta MH: Continuous glucose monitoring for hypoglycemia avoidance and glucose counterregulation in long-standing type 1 diabetes. Journal of Clinical Endocrinology & Metabolism 103(1): 105-114, January 2018 Notes: Editor's Choice.

back to top
Last updated: 12/03/2019
The Trustees of the University of Pennsylvania